Airsculpt Technologies (AIRS) reported $152M in revenue for fiscal 2025, −15.8% year on year. That ranks #2785 by revenue among 2853 SEC filers and #306 in Healthcare. It posted a net loss of −$11.7M for the same year. Revenue has grown 24.3% a year on average since 2019 ($41.2M then). The fiscal 2025 balance sheet shows $187M in total assets, $8.4M in cash and $50.6M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $152M | −15.8% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$11.6M | −$10.0M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$11.7M | −$3.6M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $3.1M | −72.7% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $2.4M | −82.8% | FY20252025-12-31 |
| Total assetsAssets | $187M | −12.0% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $87.7M | +12.2% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $8.4M | +2.6% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $50.6M | −22.7% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $39.4M | −$2.4M | Open → |
| Q2 20262026-06-30 | $42.9M | −$1.1M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Airsculpt Technologies, Inc.
- Ticker
- AIRS
- Exchange
- Nasdaq
- SIC classification
- Services-Offices & Clinics of Doctors of Medicine (8011)
- Fiscal year end
- 12-31
- CIK
- 0001870940
Filings
- 10-QAug 10, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KMar 31, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| MarimedMRMD | $160M | −$14.5M |
| LiquidiaLQDA | $158M | −$68.9M |
| Heron TherapeuticsHRTX | $155M | −$20.0M |
| Airsculpt TechnologiesAIRS | $152M | −$11.7M |
| MacrogenicsMGNX | $150M | −$74,620 |
| NeuroneticsSTIM | $149M | −$39.0M |
| Elite PharmaceuticalsELTP | $149M | $44.9M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Airsculpt Technologies — Key figures |url=https://companiesranked.com/en/company/airsculpt-technologies |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Airsculpt Technologies — Key figures. CompaniesRanked. https://companiesranked.com/en/company/airsculpt-technologiesBibTeX
@misc{companiesranked-en-company-airsculpt-technologies-2026,
author = {{CompaniesRanked}},
title = {{Airsculpt Technologies — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/airsculpt-technologies}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.